AUTHORS
Aishwarya Pradeep, MD, Meera Sridharan, MD PhD2, Dong Chen, MD, PhD3, Rong He, MD4, Juliana Perez Botero Jr, MD5, Aneel Ashrani, MD, MS6, Animesh Pardanani, PhD, MBBS7, Anand Pabmanabhan, MBBS, PhD8, Jansen N Seheult, MBBCh, BAO, MSc, MS, MD9, Richard C. Godby, MD10, Leslie Padrnos, MD11, Surbhi Shah, MBBS, MD12, Candido E Rivera, MD13, Marwan Shaikh, MD14, Ronald Go, MD15, Ewa Wysokinska, MD16, Joshua P. Slusser17, Rajiv Pruthi, MBBS18
AFFILIATIONS
1 Mayo Clinic, Rochester, Minnesota, United States
2 Mayo Clinic, Rochester, Minnesota, United States
3 Mayo Clinic, Rochester, Minnesota, United States
4 Mayo Clinic, Rochester, Minnesota, United States
5 Mayo Clinic, Rochester, Minnesota, United States
6 Mayo Clinic, Rochester, Minnesota, United States
7 Mayo Clinic, Rochester, Minnesota, United States
8 Mayo Clinic, Scottsdale, Arizona, United States
9 Mayo Clinic, Rochester, Minnesota, United States
10 Mayo Clinic, Rochester, Minnesota, United States
11 Mayo Clinic, Scottsdale, Arizona, United States
12 Mayo Clinic, Scottsdale, Arizona, United States
13 Mayo Clinic, Jacksonville, Florida, United States
14 Mayo Clinic, Jacksonville, Florida, United States
15 Mayo Clinic, Rochester, Minnesota, United States
16 Mayo Clinic, Jacksonville, Florida, United States
17 Mayo Clinic, Rochester, Minnesota, United States
18 Mayo Clinic, Rochester, Minnesota, United States
ABSTRACT
Introduction:
In a substantial proportion of patients (pts) evaluated for bleeding symptoms, when a diagnosis is unable to be established, they are diagnosed with bleeding disorder of unknown cause (BDUC). Standard hemostasis testing includes plasmatic coagulation assays, von Willebrand factor (vWF) testing, and, where available, platelet function testing (PFT) which include PFA-100 and light transmission aggregometry (LTA). In our pilot study of 108 patients with expanded testing (Pradeep et al. ASH 2025), we found abnormalities in platelet glycoproteins by flow cytometry (GpFL) and in platelet transmission electron microscopy (PTEM) in up to 30% of pts with normal hemostasis profiles. Comparison of ISTH-BAT scores in our previous subgroup between pts with normal versus abnormal standard hemostasis profiles showed no significant difference. In the current study, we expanded our retrospective analysis to a larger cohort to better define the diagnostic yield of expanded platelet testing.
Methods:
After IRB approval, in this retrospective, minimal risk study, medical records of pts who provided research authorization were reviewed. Adults (≥18 years) evaluated for a bleeding disorder at one of the 3 Mayo Clinic sites between October 2017 and March 2026 were enrolled. Eligible pts had plasma-based screening and diagnostic assays (PT, APTT, vWF assay, factor XIII screen, thrombin time, with reflex testing as indicated), PFT’s, defined as standard hemostasis profile. Addition of GpFL and PTEM was considered as an expanded profile. Clinical/demographic data and assay results were abstracted. Pts with a previously diagnosed bleeding disorder, underlying malignancy, or interfering medications (aspirin/NSAIDs, anticoagulants, SSRI’s) were excluded.
Results:
A total of 336 pts met study criteria with a median age of 48 years (range 18–89 years) and consisted primarily of females (81.3%). Among 176 patients with an abnormal standard hemostatic profile, 15 (8.5%) had a coagulation factor deficiency, 8 (4.5%) had von Willebrand disease/syndrome, 35 (19.9%) had abnormal PFA-100, 56 (31.8%) had abnormal LTA, and 62 (35.2%) had >1 of these hemostatic abnormalities. Within this group, 24 (13.6%) had abnormal PTEM findings, 20 (11.4%) had abnormal GpFL testing, and 7 (4%) had both. Ultrastructural abnormalities on PTEM included 7 with dense granule defects, 22 with alpha granule defects, and 2 with both. On GpFL testing, reduced Gp expression was as follows: GPIIb/CD41 n=7, GPIIIa/CD61 n=6, GPIa/CD49b n=14, and GPVI n=13 (some had multiple abnormalities).
Among 160 pts with normal standard coagulation profiles who would have been diagnosed with BDUC, 10 had abnormal PTEM findings, 13 had abnormal GpFL testing, and 4 had both. Ultrastructural abnormalities on PTEM included 1 with dense granule defects, 12 with alpha granule defects, and 1 with both. On GpFL testing, reduced Gp expression was as follows: GPIIb/CD41 n=3, GPIIIa/CD61 n=1, GPIa/CD49b n=8, and GPVI n=5 (some had multiple abnormalities).
Conclusion:
In this expanded cohort of bleeding disorder pts, the standard hemostasis profile resulted in a diagnosis in 176/336 (52.4%) of pts, whereas 160/336 (47.6%) would have been diagnosed with BDUC. Of the latter, expanded testing resulted in a diagnosis of a platelet disorder in 27/160 (16.9%), 48.1% of whom demonstrated alpha granule abnormalities, confirming the added value of expanded testing to include PTEM and GpFL. Follow up analysis correlating PTEM and GpFL with clinical phenotype and genotyping (if performed) are ongoing. Currently, blood samples cannot be shipped for PFTs, so the availability of sending PTEM and GpFL by mail results in increased access to diagnostic tools for clinicians and may help in distinguishing syndromic from non-syndromic platelet disorders. Traditionally, hemostatic management in BDUC consists of DDAVP and antifibrinolytics; the diagnosis of a platelet disorder expands therapeutic options to include platelet transfusions when indicated.
DISCLOSURES
Aishwarya Pradeep, MD: No relevant conflicts of interest to declare.